This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Biosimilar Etanercept (Mycenax)
Mycenax Biotech Inc.
Drug Names(s): Biosimilar Enbrel, ENIA11, ENIA 11, ENIA-11, BT-D001, BTD001, BTD 001
Mycenax's compound is a biosimilar form of etanercept (Enbrel).
Enbrel is a recombinant protein with properties of a monoclonal antibody. It is a fusion protein of the Fc (constant region) of a human antibody grafted to the ligand-binding portion of the human TNF receptor. The TNF receptor part of Enbrel functionally substitutes for an anti-TNF antibody. Blocking the activity of TNF impacts both autoimmunity and the immune response to pathogens.
Mycenax and TSH Biopharm
Mycenax and TSH Biopharm have a worldwide agreement to jointly develop biologic drugs.
Biosimilar Etanercept (Mycenax) News
Additional information available to subscribers only: